Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia

被引:47
|
作者
Anderson, Stacey M. [1 ]
Buckingham, Bruce A. [2 ]
Breton, Marc D. [1 ]
Robic, Jessica L. [1 ]
Barnett, Charlotte L. [1 ]
Wakeman, Christian A. [1 ]
Oliveri, Mary C. [1 ]
Brown, Sue A. [1 ]
Ly, Trang T. [2 ]
Clinton, Paula K. [2 ]
Hsu, Liana J. [2 ]
Kingman, Ryan S. [2 ]
Norlander, Lisa M. [2 ]
Loebner, Sarah E. [2 ]
Reuschel-DiVirglio, Suzette [2 ]
Kovatchev, Boris P. [1 ]
机构
[1] Univ Virginia, Ctr Diabet Technol, POB 400888, Charlottesville, VA 22908 USA
[2] Stanford Univ, Dept Pediat, Div Pediat Endocrinol & Diabet, Sch Med, Stanford, CA 94305 USA
关键词
Type; 1; diabetes; Hypoglycemia; Artificial pancreas; Closed-loop systems; INSULIN DELIVERY; HOME-USE; ADULTS; MULTICENTER; ADOLESCENTS; DISEASE; IDDM;
D O I
10.1089/dia.2019.0018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Typically, closed-loop control (CLC) studies excluded patients with significant hypoglycemia. We evaluated the effectiveness of hybrid CLC (HCLC) versus sensor-augmented pump (SAP) in reducing hypoglycemia in this high-risk population. Methods: Forty-four subjects with type 1 diabetes, 25 women, 37 +/- 2 years old, HbA1c 7.4% +/- 0.2% (57 +/- 1.5 mmol/mol), diabetes duration 19 +/- 2 years, on insulin pump, were enrolled at the University of Virginia (N = 33) and Stanford University (N = 11). Eligibility: increased risk of hypoglycemia confirmed by 1 week of blinded continuous glucose monitor (CGM); randomized to 4 weeks of home use of either HCLC or SAP. Primary/secondary outcomes: risk for hypoglycemia measured by the low blood glucose index (LBGI)/CGM-based time in ranges. Results: Values reported: mean +/- standard deviation. From baseline to the final week of study: LBGI decreased more on HCLC (2.51 +/- 1.17 to 1.28 +/- 0.5) than on SAP (2.1 +/- 1.05 to 1.79 +/- 0.98), P < 0.001; percent time below 70 mg/dL (3.9 mmol/L) decreased on HCLC (7.2% +/- 5.3% to 2.0% +/- 1.4%) but not on SAP (5.8% +/- 4.7% to 4.8% +/- 4.5%), P = 0.001; percent time within the target range 70-180 mg/dL (3.9-10 mmol/L) increased on HCLC (67.8% +/- 13.5% to 78.2% +/- 10%) but decreased on SAP (65.6% +/- 12.9% to 59.6% +/- 16.5%), P < 0.001; percent time above 180 mg/dL (10 mmol/L) decreased on HCLC (25.1% +/- 15.3% to 19.8% +/- 10.1%) but increased on SAP (28.6% +/- 14.6% to 35.6% +/- 17.6%), P = 0.009. Mean glucose did not change significantly on HCLC (144.9 +/- 27.9 to 143.8 +/- 14.4 mg/dL [8.1 +/- 1.6 to 8.0 +/- 0.8 mmol/L]) or SAP (152.5 +/- 24.3 to 162.4 +/- 28.2 [8.5 +/- 1.4 to 9.0 +/- 1.6]), P = ns. Conclusions: Compared with SAP therapy, HCLC reduced the risk and frequency of hypoglycemia, while improving time in target range and reducing hyperglycemia in people at moderate to high risk of hypoglycemia.
引用
收藏
页码:356 / 363
页数:8
相关论文
共 50 条
  • [1] Closed-loop blood glucose control for type 1 diabetes
    Furutani, Eiko
    ELECTRONICS AND COMMUNICATIONS IN JAPAN, 2019, 102 (07) : 22 - 26
  • [2] Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy
    Fuchs, Julia
    Hovorka, Roman
    EXPERT REVIEW OF MEDICAL DEVICES, 2020, 17 (07) : 707 - 720
  • [3] Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp
    Ly, Trang T.
    Roy, Anirban
    Grosman, Benyamin
    Shin, John
    Campbell, Alex
    Monirabbasi, Salman
    Liang, Bradley
    von Eyben, Rie
    Shanmugham, Satya
    Clinton, Paula
    Buckingham, Bruce A.
    DIABETES CARE, 2015, 38 (07) : 1205 - 1211
  • [4] Hybrid Closed-loop to Manage Gastroparesis in People With Type 1 Diabetes: a Case Series
    Daly, Aideen
    Hartnell, Sara
    Boughton, Charlotte K.
    Evans, Mark
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2021, 15 (06): : 1216 - 1223
  • [5] Closed-loop control in type 1 diabetes
    Buckingham, Bruce
    Ly, Trang
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03): : 191 - 193
  • [6] Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes
    Zhou, Keren
    Isaacs, Diana
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (09) : 1159 - 1167
  • [7] Closed-loop for type 1 diabetes - an introduction and appraisal for the generalist
    Bally, Lia
    Thabit, Hood
    Hovorka, Roman
    BMC MEDICINE, 2017, 15
  • [8] Hybrid Closed Loop in Adults With Type 1 Diabetes and Severely Impaired Hypoglycemia Awareness
    Lee, Melissa H.
    Gooley, Judith
    Obeyesekere, Varuni
    Lu, Jean
    Paldus, Barbora
    Hendrieckx, Christel
    Macisaac, Richard J.
    Mcauley, Sybil A.
    Speight, Jane
    Vogrin, Sara
    Jenkins, Alicia J.
    Holmes-Walker, D. Jane
    O'Neal, David N.
    Ward, Glenn M.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [9] Impact of Hybrid Closed Loop Therapy on Hypoglycemia Awareness in Individuals with Type 1 Diabetes and Impaired Hypoglycemia Awareness
    Burckhardt, Marie-Anne
    Abraham, Mary B.
    Dart, Julie
    Smith, Grant J.
    Paramalingam, Nirubasini
    O'Dea, Joanne
    de Bock, Martin
    Davis, Elizabeth A.
    Jones, Timothy W.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (07) : 482 - 490
  • [10] Glycemic control metrics in a cohort of hospitalized patients with type 1 diabetes using hybrid closed-loop and advanced hybrid closed-loop systems
    Medina, Ana Maria Gomez
    Henao-Carrillo, Diana Cristina
    Yepes, Carlos
    Silva, Julio
    Gomzalez, Javier Alberto Gomez
    Cortes, David
    Robledo, Sofia
    Mejia, Gabriela
    Rondon, Martin
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 204